title: The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw.
abstract: There is an increasing use of established and newer medications that have antiangiogenic properties. Inhibition of angiogenesis likely has either a primary or secondary role in the development of osteonecrosis of the jaw (ONJ). These medications are being used in the treatment of various cancers and in the treatment of several non-oncologic conditions. Antiangiogenic medications when used in combination with antiresorptive medications, such as nitrogen-containing bisphosphonates or denosumab, seem to increase the likelihood of osteonecrosis of the jaw. This review highlights the role of inhibitors of angiogenesis and their role in the development of osteonecrosis of the jaws.
authors.affiliation: Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Hofstra North Shore-LIJ School of Medicine, 270-05 76th Avenue, New Hyde Park, NY 11040, USA. Electronic address: fantasia@lij.edu.
authors.forename: John E
authors.initials: JE
authors.lastname: Fantasia
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000453:epidemiology; D000069448:Denosumab / Q000009:adverse effects; D004164:Diphosphonates / Q000009:adverse effects; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000453:epidemiology; D010020:Osteonecrosis / Q000139:chemically induced* / Q000453:epidemiology; D012307:Risk Factors
chemical_list: D020533:Angiogenesis Inhibitors; D004164:Diphosphonates; D000069448:Denosumab
keywords: Antiangiogenic therapy; Denosumab; Mammalian target of rapamycin inhibitors; Nitrogen-containing bisphosphonates; Receptor activator of nuclear factor-κB ligand inhibitors; Tyrosine kinase inhibitors; Vascular endothelial growth factor inhibitors